Prospective Study of Bevacizumab Plus Temozolomide in Patients With Advanced Neuroendocrine Tumors

PURPOSE: Both tyrosine kinase inhibitors targeting the vascular endothelial growth factor (VEGF) receptor and bevacizumab, a monoclonal antibody targeting VEGF, have antitumor activity in neuroendocrine tumors (NETs). Temozolomide, an oral analog of dacarbazine, also has activity against NETs when a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Chan, Jennifer A., Stuart, Keith, Earle, Craig C., Clark, Jeffrey W., Bhargava, Pankaj, Miksad, Rebecca, Blaszkowsky, Lawrence, Enzinger, Peter C., Meyerhardt, Jeffrey A., Zheng, Hui, Fuchs, Charles S., Kulke, Matthew H.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2012
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4874232/
https://ncbi.nlm.nih.gov/pubmed/22778320
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.40.3147
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados